InvestorsHub Logo
Followers 113
Posts 25553
Boards Moderated 4
Alias Born 02/01/2004

Re: None

Friday, 09/22/2006 1:47:40 PM

Friday, September 22, 2006 1:47:40 PM

Post# of 5055
Ancer 20 = Z-100

Note:
New Immune-Based Treatment Approach: Trial Recruiting in San Francisco. will be studied in San Francisco - Z-100 Ancer 20
AIDS Treatment News, Feb 23, 2001 by John S. James

A new kind of potential treatment is about to begin its first human trial in San Francisco.

A drug called Z-100 (also called Ancer 20) has been approved for years in Japan and used by thousands of patients there to stimulate growth of blood cells after cancer therapy; doctors use it when filgrastim (Neupogen(R)) would be used in the U.S. The drug, prepared from the cell walls of the bacterium that causes tuberculosis and injected in very small amounts, stimulates the production of many cytokines in the process of causing blood cell growth - and has been found to increase the production of MIP-l-alpha, which can help block many HIV variants from entering cells, in laboratory tests with cells from patients with HIV[1]. It appears to change the immune response from Th2 toward Thl, which may be useful in controlling this virus.

Laboratory tests with HIV found that Z-100 alone did not reduce the growth of the virus - but did reduce viral growth when combined with a concentration of AZT which was too low to be effective in itself[2]. These studies are only suggestive, because patients usually respond differently than cells in a laboratory culture.
http://findarticles.com/p/articles/mi_m0HSW/is_2001_Feb_23/ai_71767161

Also see:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...
http://chemdb.niaid.nih.gov/struct_search/all/url_search.asp?
http://www.niaid.nih.gov/daids/dtpdb/index.asp
http://www.siliconinvestor.com/readmsg.aspx?msgid=22409038

The SEC Must Go!
And jail shorters.



Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.